Categories: NewsPharmaceutical

Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

WALTHAM, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the SVB Securities Virtual Global Biopharma Conference on Wednesday, February 15, 2023 at 1:00 p.m. ET.

A live webcast of the fireside chat can be accessed under “Events and Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com. A replay of the webcast will be available following the completion of the event.

About Viridian Therapeutics

Viridian Therapeutics is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and engineering enables it to develop differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company recently initiated its first global Phase 3 trial called ‘THRIVE’ to evaluate the safety and efficacy of VRDN-001 in patients with active TED. Viridian is also evaluating VRDN-001 in a Phase 2 proof-of-concept trial in patients with chronic TED. In addition to its intravenously administered VRDN-001 program, the Company is advancing two candidates for its subcutaneous strategy with the goal of providing a more conveniently administered therapy to patients with TED. Viridian is developing multiple preclinical assets in autoimmune and rare diseases.

Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn.

Investor and Media Contact:

Viridian Therapeutics, Inc.

Louisa Stone, 508-808-2400
Manager, Investor Relations
IR@viridiantherapeutics.com

Todd James, 617-272-4691
Senior Vice President, Corporate Affairs and Investor Relations
IR@viridiantherapeutics.com

Source: Viridian Therapeutics, Inc.

Staff

Recent Posts

Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it…

2 hours ago

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on…

2 hours ago

GE HealthCare and NVIDIA reimagine diagnostic imaging with autonomous X-ray and ultrasound solutions

Building on its 125-year legacy of medical imaging innovation and a 16-year relationship with NVIDIA,…

2 hours ago

Apollo Biowellness, Inc., f/k/a Resonate Blends Announces Management Changes

North Bergen, New Jersey--(Newsfile Corp. - March 19, 2025) - Apollo Biowellness, Inc. formerly known…

2 hours ago

Sona Presents Additional Preclinical Data Demonstrating Repeated Ability Of Its Cancer Therapy To Inhibit Tumor Growth In Colorectal Cancer Model

Halifax, Nova Scotia--(Newsfile Corp. - March 19, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB:…

2 hours ago

New Psilocybin Service Center Opens to Support Athletes, Veterans, and Others with Traumatic Brain Injuries

Founded by Former NHL Player and mental health advocate Daniel Carcillo, the Portland center is…

2 hours ago